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Background: Hypoxic niches in solid tumors harbor therapy-resistant cells. Hypoxia-activated prodrugs (HAPs) have
been designed to overcome this resistance and, to date, have begun to show clinical efficacy. However, clinical
HAPs activity could be improved. In this study, we sought to identify non-pharmacological methods to acutely
exacerbate tumor hypoxia to increase TH-302 activity in pancreatic ductal adenocarcinoma (PDAC) tumor models.
Results: Three human PDAC cell lines with varying sensitivity to TH-302 (Hs766t > MiaPaCa-2 > SU.86.86) were used
to establish PDAC xenograft models. PDAC cells were metabolically profiled in vitro and in vivo using the Seahorse
XF system and hyperpolarized 13C pyruvate MRI, respectively, in addition to quantitative immunohistochemistry. The
effect of exogenous pyruvate on tumor oxygenation was determined using electroparamagnetic resonance (EPR) oxygen
imaging. Hs766t and MiaPaCa-2 cells exhibited a glycolytic phenotype in comparison to TH-302 resistant line SU.86.86.
Supporting this observation is a higher lactate/pyruvate ratio in Hs766t and MiaPaCa xenografts as observed during
hyperpolarized pyruvate MRI studies in vivo. Coincidentally, response to exogenous pyruvate both in vitro (Seahorse
oxygen consumption) and in vivo (EPR oxygen imaging) was greatest in Hs766t and MiaPaCa models, possibly due to
a higher mitochondrial reserve capacity. Changes in oxygen consumption and in vivo hypoxic status to pyruvate were
limited in the SU.86.86 model. Combination therapy of pyruvate plus TH-302 in vivo significantly decreased tumor
growth and increased survival in the MiaPaCa model and improved survival in Hs766t tumors.
Conclusions: Using metabolic profiling, functional imaging, and computational modeling, we show improved TH-302
activity by transiently increasing tumor hypoxia metabolically with exogenous pyruvate. Additionally, this work
identified a set of biomarkers that may be used clinically to predict which tumors will be most responsive to
pyruvate + TH-302 combination therapy. The results of this study support the concept that acute increases in
tumor hypoxia can be beneficial for improving the clinical efficacy of HAPs and can positively impact the future
treatment of PDAC and other cancers.
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Tumor hypoxia, a routinely observed phenotype, contrib-
utes to chemo- and radioresistance, causing major thera-
peutic concern [1]. Due to extensive hypoxia, considerable
effort has been devoted to harness its therapeutic potential.
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unless otherwise stated.(HAPs) has been developed to selectively target tumor
cells residing in hypoxic niches [2,3]. The most common
class of HAPs is based on 2-nitroimidazoles, exemplified
by TH-302, which is activated by cytochrome P450
reductase and contains alkylating nitrogen mustard,
Br-isophosphoramide, as a cytotoxic effector [4]. There
are 12 clinical trials with TH-302 underway in a variety
of cancers (e.g., pancreatic, sarcoma, breast, melanoma)
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of tumor hypoxia [5]. We therefore hypothesized that
increasing tumor hypoxia could improve TH-302 activity.
Experimental evidence show that the most effective ap-
proach to decrease tumor oxygenation (pO2) is increasing
the oxygen consumption rate (OCR) [6]. This was effect-
ive in RKO cells in which pharmacological inhibition of
hypoxia-inducible factor 1-alpha (HIF-1α) with echinomy-
cin increased OCR, decreased tumor pO2, and increased
the activity of the HAP, tirapazamine [7]. While HIF-1α
inhibition was effective at increasing OCR, pharmaco-
logical inhibition may induce chronic hypoxia that could
promote further adaptation and possibly increased HAP
side effects. A separate study demonstrated that [1-13C]
pyruvate infusion during hyperpolarized MRI studies sub-
stantially decreased tumor pO2 and increased hypoxia in
squamous cell carcinoma (SCC) tumors [8]. The effect
was transient, with peak hypoxia observed at 30 min,
returning to baseline within 5 h. Pyruvate also stimulates
OCR across a panel of breast cancer cell lines [9], consist-
ent with historical data that shows increased OCR in
response to pyruvate (or lactate) in neurons and cardiac
myocytes [10-12]. Because pyruvate 1) transiently decreases
tumor pO2, 2) decreases tumor pO2 metabolically rather
than pharmacologically, and 3) produces no detectable side
effects, we hypothesize that pyruvate would be a successful
adjuvant to enhance TH-302 efficacy.
A consequence of a desmoplastic stroma is poor per-
fusion, particularly in pancreatic ductal adenocarcinoma
(PDAC). PDAC tumors are profoundly hypoxic in com-
parison to normal pancreatic tissue [13] which is a negative
prognostic factor [14]. TH-302 is highly effective in pre-
clinical pancreatic models [15] and has been effective in
phase I/II trials in combination with gemcitabine (GEM),
increasing progression-free survival of late-stage cancers by
2 months [16]. These encouraging results justified a phase
III trial, which is ongoing (NCT01746979).
In the present study, we utilized PDAC models to dem-
onstrate the ability of exogenous pyruvate to stimulate
oxygen consumption in vitro and transiently decrease
tumor pO2 in vivo. The decrease in tumor pO2 correlated
with improved TH-302 efficacy, demonstrated by signifi-
cant tumor volume decreases and increased survival.
We also identified potential imaging and histological
biomarkers that can be used to predict responsive tumor
types. These data support the concept that temporarily
increasing tumor hypoxia can improve the efficacy of
HAPs, including TH-302, against PDAC and other cancer
types in the clinic.
Methods
Cell culture
SU.86.86 and Hs766t cells were obtained from Threshold
Pharmaceuticals (Redwood City, CA, USA), and MiaPaCa-2 cells were obtained from American Type Cell Collection
(ATCC, Manassas, VA, USA). The cells were maintained
in RPMI-1640 (Life Technologies) supplemented with
10% fetal bovine serum (FBS) (HyClone) (SU.86.86) and
Dulbecco’s modified Eagle’s medium-F12 (DMEM-F12)
(Life Technologies) supplemented with 10% FBS (Hs766t
and MiaPaCa-2). All three cell lines were resuscitated
from low passage with all experiments carried out with
cells of passage numbers less than 10 (SU.86.86) and 20
(Hs766t and MiaPaCa-2).
Animal housing
All animal experiments were carried out at the Moffitt
Cancer Center and National Cancer Institute in compli-
ance with the Guide for the Care and Use of Laboratory
Animal Resources [17]. Experimental protocols con-
ducted at Moffitt Cancer Center were approved by the
Institutional Animal Care and Use Committee, University
of South Florida. Experimental protocols performed at
the National Cancer Institute were approved by the
Institutional Animal Care and Use Committee, National
Cancer Institute.
Tumor development and treatment
Hs766t, MiaPaCa-2, and SU.86.86 pancreatic cancer
cells were suspended in Matrigel Matrix (BD Biosci-
ences, Franklin Lakes, NJ, USA) and phosphate-buffered
saline (PBS) (1:1). Female SCID mice (6 weeks) (Harlan
Inc., Indianapolis, IN, USA) were inoculated with 5 ×
106–10 × 106 cells (matrigel/PBS) subcutaneously on
the right flank to form xenograft tumors. Tumor vol-
ume was determined twice per week by caliper until
the volume reached 300 mm3 upon which the mice
were randomly placed into treatment groups (N = 10 per
group). Treatment groups consisted of saline control, TH-
302 (50 mg/kg (Figure 1) and 80 mg/kg) and pyruvate
(1.15 mmol/kg) (Sigma-Aldrich, St. Louis, MO, USA)
plus TH-302. TH-302 was administered IP five times
per week for 2 weeks. Pyruvate was administered IV
30 min prior to TH-302 in combination studies. The
tumor volumes were followed twice per week by
caliper. Mice with tumors reaching 2,000 mm3 were
removed from the study.
Immunohistochemistry
Surgically removed pancreatic xenografts were formalin
fixed and paraffin embedded (FFPE). Untreated xenograft
tissue cross sections were stained for carbonic anhydrase
IX (anti-rabbit AB15086; Abcam, Cambridge, MA, USA),
lactate dehydrogenase V (anti-rabbit AB9002; Abcam),
monocarboxylate transporter 1 (anti-rabbit SC-50324; Santa
Cruz Biotechnology, Santa Cruz, CA, USA), and CD31
(anti-rabbit AB28364; Abcam). PDAC xenografts treated
with TH-302 (50 mg/kg) for 48 h were formalin fixed,
Figure 1 Tumor hypoxia is main determinant for TH-302 Therapy. (a-c) Monotherapy TH-302 efficacy in Hs766t (a), MiaPaCa-2 (b) and SU.86.86
(c) tumors (50 mg/kg x 3 days/week x 2 weeks). Black bar represents administration of treatment. N=10 animals per treatment group. (d) Pimonidazole
staining as biomarker of physical tumor hypoxia. Pimonidazole Hydrochloride was injected 2hr prior to tumor removal. Scale Bar = 300 μM (e)
Carbonic Anhydrase IX (CAIX) staining as biomarker for tumor biological hypoxia. PPC analysis identified Hs766t and MiaPaCa-2 tumors as expressing
significantly more CAIX than SU.86.86 tumors. (f) Histological staining of g-H2AX in PDAC tumors pre- and 48hr post-TH-302 treatment (50 mg/kg). (g)
Nuclear stain intensity analysis of g-H2AX staining. g-H2AX significantly increased in Hs766t and MiaPaCa-2 Th-302 treated tumors. Data are presented
as mean ± S.D of three tumor samples. A two-tailed Student’s t-test was used to determine significance. # p=0.06, ** p<0.01, ***, p<0.001. Scale
Bar = 100 μM. See also Additional file 1: Figure S2.
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dazole hydrochloride (60 mg/kg; Hypoxyprobe Inc.) was
injected I.P. 1 h prior to tumor removal. Pimonidazole-positive tissue was detected using rabbit anti-sera against
pimonidazole hydrochloride (2,627; Hypoxyprobe Inc.).
A tissue microarray (TMA) containing FFPE human
Figure 2 In vitro metabolic analysis of PDAC cell lines. Basal oxygen consumption rates [OCR (pMoles/min/mg protein)] (a), proton
production rates [PPR (pMoles/min/mg protein)] (b) and OCR/PPR (c) measurements acquired using XF96 for all three PDAC cell lines. Data
presented as mean ± S.D. (d) Mitochondrial bioenergetics profile indicates SU.86.86 cells as more oxidative than Hs766t and MiaPaCa-2 cells.
Oligo = 1 μM oligomycin, FCCP = 1 μM FCCP and Rot/Ant = 1 μM Rotenone and 1 μM Antimycin A. (e) Glycolytic bioenergetics profile shows
MiaPaCa-2 and Hs766t cells exhibit a glycolytic phenotype in comparison to SU.86.86 cells. Gluc = 12 mM D-Glucose, Oligo = 1 μM Oligomycin
and 2-DG = 50 mM 2-Deoxyglucose. (f-h) ΔOCR following dose dependent administration of exogenous sodium pyruvate. Data are presented
as mean ± S.D of three replicate studies. A two-tailed Student’s t-test was used to determine significance. * p<0.05, ** p<0.01, ***, p<0.001,
**** p<0.0001. See also Additional file 1: Figures 3 and 4. (i) Percent glucose uptake and (j) percent pyruvate uptake presented relative to T=0
substrate concentrations. Data are presented as mean ± S.D. of three replicates.
Wojtkowiak et al. Cancer & Metabolism  (2015) 3:2 Page 4 of 13pancreatic adenocarcinoma specimen, acquired from
Moffitt Cancer Center Total Cancer Care tissue database,
was stained with antibodies against monocarboxylate
transporter 1, monocarboxylate transporter 4 (anti-rabbitSC-376140; Santa Cruz Biotechnology), and pyruvate
kinase isoform M2 (anti-mouse #3198; Cell Signaling
Technology Inc., Danvers, MA, USA). The Ventana
OmniMap anti-rabbit or anti-mouse secondary was used
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was the Ventana ChromoMap Kit, and slides were then
counterstained with hematoxylin. Histology stained slides
were scanned using the Aperio ScanScope XT.
Seahorse XF metabolic assays
In vitro metabolic analysis using the XF96 (Seahorse Bio-
science, Chicopee, MA, USA) was previously described
[18]. Briefly, real-time OC (pMole/min) and proton
production rates (PPR, pMole/min) are determined by
measuring oxygen and free protons in the media over a
monolayer of cells. All collected data are normalized to
protein using a standard BCA protein assay. Data are
presented as the normalized mean ± standard deviation
(S.D.)/mg protein.
Mitochondrial stress test
ATP-linked OCR and mitochondrial reserve capacity
were determined following the sequential injections of
oligomycin (1 μM), carbonyl cyanide-p-trifluoromethox-
yphenylhydrazone (FCCP) (1 μM), and rotenone plus
antimycin A (1 μM). ATP-linked oxygen consumption is
determined by the difference between basal OCR and
OCR following addition of oligomycin. Mitochondrial
reserve capacity is defined as the difference of basal
OCR and OCR following the addition of FCCP.
Glycolysis stress test
Glycolysis and glycolytic capacity were determined follow-
ing sequential injections of D-glucose (2 g/L), oligomycin
(1 μM), and 2-deoxyglucose (100 mM). Initially, the cells
are glucose starved for 2 h prior to experiment start.
Glycolysis was defined as PPR following the addition of
D-glucose, and maximum glycolytic capacity was defined
as PPR following the addition of oligomycin. PPR fol-
lowing treatment with 2-deoxyglucose is associated with
non-glycolytic activity.
Glucose and pyruvate uptake assay
Glucose (K676) and pyruvate (K609) uptake from culture
media was measured using colometric from BioVision Inc.
The PDAC cells were seeded in standard growth media
(see “Cell culture” section) and allowed to adhere over-
night. At T = 0, the cells were rinsed twice with PBS and
provided DMEM supplemented with 5.5 mM D-glucose,
1 mM L-glutamine, 2 mM sodium pyruvate, and 0.2%
FBS. Following 12 h of culture time, the media were col-
lected, centrifuged to remove cell debris, and immediately
tested for glucose and pyruvate following BioVision assay
kit protocols and compared to starting media conditions.
Absorbance was quantified at 570 nM. Data are presented
as percent substrate uptake (mean ± S.D.) relative to T = 0
culture media concentrations.EPR imaging
A pulsed electroparamagnetic resonance (EPR) scanner
with a parallel coil resonator tuned to 300 MHz was
used for oxygen imaging. After the mouse was placed in
the resonator, triarylmethyl EPR oxygen tracer OX063
(1.125 mmol/kg bolus followed by 0.12 mmol/min of
continuous infusion) was administrated via tail veil can-
nula. Single-point imaging with a three-gradient set was
used to generate T2
* map, i.e., EPR line width map, which
linearly correlates with local concentration of oxygen
and allows pixelwise estimation of pO2. In total, four
pO2 maps were obtained for each mouse before, 10, 30,
and 60 min after IV injection of pyruvate (1.15 mmol/kg,
bolus). After EPR study, the mice were transferred to a
7T MRI scanner (Bruker Bio-Spin MRI GmbH) for
anatomic imaging.
Mathematical model
The previously developed mathematical model microPD
[19], which couples the reaction-diffusion/convection
equations with the fluid-structure interaction methods
on spatially explicit tissue structure, has been calibrated
to match the histology of MiaPaCa-2 mouse xenograft,
the PK/PD properties of oxygen, and both inactive and
active TH-302 (Additional file 1: Methods). The simula-
tions were executed, visualized, and analyzed using a suite
of in-house Matlab routines. Tissue histology was digitized
using ImageJ software and in-house Matlab routines.
Statistical analysis
A two-tailed unpaired Student’s t-test was used to deter-
mine statistical significance. The significance level was
set at p < 0.05.
Results
Identifying baseline TH-302 sensitivity in human PDAC
tumor models
Three human PDAC cell lines (Hs766t, MiaPaCa-2, and
SU.86.86) were used to evaluate the effect of exogenous
pyruvate on tumor hypoxia and TH-302 efficacy. Sub-
cutaneous tumors were shown to be histologically (H&E)
similar to pancreatic orthotopic tumors (Additional file 1:
Figure S1). These were used to accommodate imaging
modalities used to monitor pyruvate metabolism and
tumor oxygenation, which cannot currently be made with
orthotopic PDAC tumors. TH-302 monotherapy studies
were carried out against each tumor type. The greatest
anti-tumor effect occurred in Hs766t tumors. MiaPaCa-2
tumors had an intermediate response, and SU.86.86
tumors displayed no sensitivity to TH-302 (Figure 1a–c).
As hypoxia is the main determinant for TH-302 activity,
immunohistochemistry (IHC) detecting pimonidazole and
carbonic anhydrase IX, respectively, markers for physical
[20] and biological [21] hypoxia, confirmed the greatest
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carry a nonsense mutation in FANCG [22] rendering them
deficient in DNA repair and hence sensitizing them to
alkylating agents, such as Br-ifosphoramide, the effector
agent in TH-302. To confirm sensitivity to such agents, all
three lines were treated with DNA cross-linking agent,
mitomycin C (MMC), under normoxic conditions. Hs766t
cells exhibited extreme sensitivity to low nanomolar con-
centrations of MMC (IC50 = 2.8 nM) in comparison to
MiaPaCa-2 (IC50 = 15.1 nM) and SU.86.86 (IC50 = 29.7
nM) cells which carry no detectable DNA repair defects
(Additional file 1: Figure S2a). Negligible TH-302 activity
in SU.86.86 may be attributed to a well-oxygenated tumor
environment as evidence by low CA9 expression and
reduced sensitivity to DNA cross-linking agents. In vivo
tumor doubling times also correlated with TH-302 sen-
sitivity, as faster growing tumors (Hs766t) were more
hypoxic and sensitive to TH-302 than slower growing tu-
mors (SU.86.86), which we interpret as a higher propen-
sity to outgrow existing blood vessels (Additional file 1:
Figure S2b). Quantification of vascular density based
on CD31 staining supports this observation as Hs766t
(p = 0.0526) and MiaPaCa-2 (p = 0.0189) tumors had less
vascular density than SU.86.86 tumors (Additional file 1:
Figure S3). Th-302 toxicity was validated by quantifica-
tion of γ-H2AX, a DNA damage response reporter [5]
(Additional file 1: Figure S2d). γ-H2AX increased in
treated Hs766t (p = 0.004) and MiaPaCa-2 (p = 0.061)
tumors with no change in SU.86.86 tumors (p = 0.669)
(Figure 1f,g).
Pyruvate stimulates oxygen consumption in glycolytic cells
The Seahorse XF96 was used to determine metabolic
phenotypes (i.e., oxidative or glycolytic) for each cell line.
The OCR of Hs766t (42 pMoles/min/mg) and MiaPaCa-
2 (40 pMoles/min/mg) cells were significantly lower
than that of SU.86.86 (65 pMoles/min/mg) (Figure 2a).
Mitochondrial stress tests indicated that SU.86.86 cells
had greater ATP-linked OCR and mitochondrial reserve
capacity than Hs766t and MiaPaCa-2 cells, implying that
the SU.86.86 cells are more oxidative (Figure 2d and
Additional file 1: Figure S4a–c). Consistent with this inter-
pretation, Hs766t and MiaPaCa-2 cells exhibited glycolytic
phenotypes. Glucose-stimulated acid production (PPR) for
Hs766t (179 pMoles/min/mg) and MiaPaCa-2 (275
pMoles/min/mg) cells were higher than that for SU.86.86
(87 pMoles/min/mg) (Figure 2b). ATP-linked glycolysis
and glycolytic capacity were also greater in Hs766t and
MiaPaCa-2 cells (Figure 2e and Additional file 1: Figure
S4d–f ). Glucose consumption was quantified and
shown to be greatest in Hs766t and least in SU.86.86
cells partially supporting the Seahorse metabolic data
(Figure 2i). These metabolic data suggest that Hs766t and
MiaPaCa-2 cells are better suited to thrive under hypoxicconditions. Interestingly, SU.86.86 cells grew better
under hypoxia than Hs766t and MiaPaCa-2 cells, even
though the latter cell lines exhibited glycolytic pheno-
types and formed more hypoxic tumors (Additional file
1: Figure S2c).
Pyruvate was administered to cells in increasing doses
(0–2 mM) with expectations that respiration would
increase. 2 mM pyruvate stimulated the largest OCR re-
sponse (Figure 2f–h). Hs766t cells exhibited the largest
relative increase and SU.86.86 cells the lowest, despite the
fact that they had the largest oxidative reserve (Additional
file 1: Figure S5e). No significant difference of pyruvate
consumption was observed between cell lines, suggesting
that intracellular pyruvate utilization may differ between
cell lines (Figure 2j). PPR response to pyruvate was
inversely related to OCR, presumably due to a reduction
in net acid production (i.e., lactate derived from pyruvate
rather than glucose), as well as a greater concentration of
pyruvate entering the tricarboxylic acid cycle (TCA) cycle
(Additional file 1: Figure S5a–d). Mitochondrial mem-
brane potential increased following administration of 4
mM pyruvate in SU.86.86 cells as determined using
tetramethylrhodamine ethyl ester (TMRE), confirming
stimulation of the TCA cycle (Additional file 1: Figure S5f).
These data indicate that cells with a glycolytic phenotype
are more susceptible to pyruvate-stimulated OCR than
oxidative SU.86.86 cells.
We performed 13C magnetic resonance spectroscopy
(MRS) of hyperpolarized [1-13C]pyruvate to validate the
metabolic phenotypes in vivo. The pyruvate-to-lactate
conversion in real-time is shown (Figure 3a–f ), and the
flux ratio (Lac/Pyr) was calculated from the area under
the curve (AUC) for lactate and pyruvate versus time
(N = 4). The Lac/Pyr flux ratio in Hs766t and MiaPaCa-2
tumors were significantly greater than that in SU.86.86
tumors (Figure 3g). Apparent rate constants kP (Pyr/Lac)
and kL (Lac/Pyr) were calculated using modified Bloch
equations [23]. The kP/kL ratio was significantly higher
in Hs766t (3.3 ± 0.5) and MiaPaCa-2 (3.4 ± 0.4) than
SU.86.86 (2.7 ± 0.4) tumors. The Lac/Pyr flux and kP/kL
ratios corresponded with the glycolytic phenotype of
Hs766t and MiaPaCa-2 observed in vitro (Figure 2e and
Additional file 1: Figure S4d–f). Hs766t and MiaPaCa-2
tumors also histologically exhibited higher lactate dehydro-
genase A protein expression than SU.86.86 (Figure 3h,i).
Pyruvate transiently decreases tumor oxygenation
Electron paramagnetic resonance imaging (EPRI) was used
to quantify changes in tumor pO2 following pyruvate
administration [8]. Following anatomic MRI (left column
(T2W)) and prior to EPRI, the triarylmethyl radical
(TAM) OX063 tracer was injected intravenously (IV)
and baseline tumor pO2 determined (Figure 4a–c).
Hs766t and MiaPaCa-2 tumors were hypoxic with a
Figure 3 Dynamic 13C MR spectra following intravenous administration of pyruvate. 13C MR spectra from Hs766t (a), MiaPaCa-2 (c) and
SU.86.86 (e) tumors. N=4 tumors per cell line. Pyruvate and lactate peaks are at 171 and 183 ppm respectively. Spectra were collected every 2
second. T2 weighted axial MR images containing slice ROI (red box) are inset. Tumor lactate and pyruvate peak intensities are shown with time
for Hs766t (b), MiaPaCa-2 (d) and SU.86.86 (f) tumors. (g) Lactate to pyruvate ratio (Lac/Pyr) for all three tumor types. (N=4 tumors for each group
and presented as mean ± S.D.). (h) Lactate Dehydrogenase A (LDHA) histological staining and (i) PPC analysis in all three PDAC tumors.
Expression of LDHA was significantly greater in Hs766t and MiaPaCa-2 tumors in comparison to SU.86.86. Data are presented as mean ± S.D of
four biological replicates. A two-tailed Student’s t-test was used to determine significance. * p<0.05. Scale Bar = 100 μM.
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(Figure 4d). Approximately 50% of the tumor volumes
had a pO2 < 10 mmHg (Figure 4e), the pO2 at which
TH-302 is activated [24]. The SU.86.86 tumors were less
hypoxic with a mean tumor pO2 of 17.6 ± 2.6 mmHg. Pre-
viously published data show that the pO2 of normal
mouse muscle is 20.8 ± 3.3 mmHg [25]. Only 28% of
SU.86.86 tumor volumes had a pO2 < 10 mmHg. SU.86.86
consumed O2 at a higher rate in vitro, indicating that
although there is no direct correlation between OCR andhypoxia in the steady state, it is likely modulated by the
vascular oxygen supply. Hence, SU.86.86 tumors are
better perfused, as observed by the higher AUC for pyru-
vate delivery (Figure 3f). Pyruvate (1.15 mMol/kg) was ad-
ministered IV and tumor pO2 monitored and presented as
mean tumor pO2 and hypoxic fraction (HF) of the en-
tire tumor region. In SU.86.86 and Hs766t tumors, the
greatest decrease in pO2 was observed 30 min post in-
jection with pO2 recovering by 60 min (Figure 4a–d).
In MiaPaCa-2 tumors, the pO2 continued to decline
Figure 4 (See legend on next page.)
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Figure 4 EPR tumor oxygen imaging following administration of exogenous pyruvate. (a–c) EPR oxygen imaging of subcutaneous Hs766t
(a), MiaPaCa-2 (b), and SU.86.86 (c) tumors pre- and post (10–60 min) IV pyruvate administration. Representative T2 weighted anatomical MR
imaging and pO2 maps are provided N = 4 biological replicates per tumor type. (d) Temporal changes of mean pO2 and (e) percent hypoxic
fraction (<10 mmHg) of pyruvate-treated PDAC tumors. Data presented as mean ± S.D. Proposed histological predictive biomarkers for pyruvate
sensitivity. (f) Histological staining of monocarboxylate transporter (MCT) 1 expression in PDAC subcutaneous tumors. Corresponding images
of positive pixel membrane staining are included. Human PDAC tissue microarray stained for MCT1 (g), MCT4 (h), and pyruvate kinase isoform M2
(i). (j) Distribution of percent positivity across well-differentiated human PDAC tissue cores. Scale bar = 100 μM. See also Additional file 1: Figure S5.
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The HF (pixels <10 mmHg) significantly increased in both
MiaPaCa-2 (22%) and Hs766t (12%) tumors. SU.86.86
baseline HF (28%) was considerably lower than the other
two tumor types, increasing only 7%, 30 min after admin-
istering pyruvate, and returning to near baseline by 60
min (Figure 4e). Representative frequency histograms of
tumor pO2 demonstrated a leftward shift after pyruvate
administration in Hs766t and MiaPaCa-2 tumors with an
increased percentage of pixels <10 mmHg (Figure 4f–h
and Additional file 1: Figure S6a–f ). The sensitivity of
Hs766t and MiaPaCa-2 tumors to pyruvate in vivo corrob-
orate the in vitro metabolic profiling studies (cf. Figure 2).
Additionally, low tumor pO2 and high HF of Hs766t and
MiaPaCa-2 tumors at baseline may contribute to their
native sensitivity to TH-302 monotherapy (Figure 1).
To investigate underlying mechanisms for pyruvate
sensitivity in vivo, untreated pancreatic tumors were stainedFigure 5 In vivo effect of pyruvate pretreatment on improving TH-30
and SU.86.86 (c) tumors were treated with saline, TH-302 alone (80 mg/kg × 5
pyruvate (1.15 mMol/kg pyruvate IV 30 min prior to 80 mg/kg TH-302 I.P. × 5
mice are removed from study when tumors reach 2,000 mm3. Pyruvate pretre
MiaPaCa-2 tumors with no measurable effect against SU.86.86. (d) Mean survi
302 in combination with pyruvate pre-treatment. N = 10 mice per treatment g
significance. **p < 0.01.for monocarboxylate transporter 1 (MCT-1), a high affinity
Pyr/Lac membrane transporter (Km= 0.7 mM/3.5 mM)
[26] (Figure 4f). Expression was higher in Hs766t and
MiaPaCa-2 tumors, compared to SU.86.86. MCT-1 was
quantified per cell, shown as a heat map in the lower panels
of Figure 4f. Expression was heterogeneous with relatively
small populations of high MCT-1 expressing cells (red) sur-
rounded by low expressing cells (yellow or blue). To deter-
mine if this histological observation was clinically relevant,
we stained a human PDAC tissue microarray for MCT-1
and additional glycolytic markers, PKM2 and MCT-4 [27]
(Figure 4g–j). All markers exhibited strong staining patterns
in poorly differentiated ductal epithelial cells, as well as in
stromal fibroblasts, indicating that stromal cells have al-
tered metabolic activity, similar to the cancer cells. Stroma
exhibiting such staining patterns may also contribute to
hypoxic exacerbation by increasing respiration in their
compartment, and this is under active investigation.2 efficacy. Percent local tumor control of Hs766t (a), MiaPaCa-2 (b),
days I.P.) or TH-302 following a 30 min pretreatment with exogenous
days). Response was measured as percentage of surviving animals as
atment significantly improved local control of Hs766t (p < 0.00225) and
val (days) of mice with pancreatic tumors treated with TH-302 and TH-
roup. A two-tailed Student’s t-test was used to determine
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Since TH-302 is activated below 10 mmHg, we predicted
that pyruvate pretreatment (30 min) would enhance TH-
302 efficacy in Hs766t and MiaPaCa-2 tumors with little
to no anticipated benefit in SU.86.86 tumors, as pyruvate
had little effect on hypoxia in this model. PDAC tumors
were established, and the mice were randomized into
three treatment groups: 1) saline control, 2) TH-302
alone, and 3) pyruvate + TH-302 (pyruvate 30 min prior
to TH-302). Data are presented as percent local control
of tumor growth. SU.86.86 tumors remained resistant to
TH-302 alone with no benefit in survival when combined
with pyruvate (Figure 5c,d). Pyruvate had no effect on the
initial Hs766t TH-302 tumor response, as they were
already maximally responsive (Figure 1a). However, pyru-
vate pretreatment significantly improved overall Hs766t
survival (Figure 5a,d) with 50% of the animals surviving
beyond 54 days, at which time all animals in the other
groups had expired. MiaPaCa-2 tumors exhibited the
greatest decrease in tumor pO2 by exogenous pyruvate
(Figure 4). These tumors received the greatest benefit
from pyruvate pretreatment with a significant delay in
tumor growth compared to both saline control and
TH-302 monotherapy groups. Combining pyruvate with
TH-302 increased the time to reach 2,000 mm3 compared
to tumors treated with TH-302 monotherapy (p < 0.05)
and overall survival significantly increased by 9.7 days
(p < 0.005 in the pyruvate plus TH-302 treatment group
compared to saline control) and by 4.7 days, compared to
TH-302 monotherapy (log rank p < 0.05) (Figure 5b,d).
MicroPD model
The pharmacokinetics of combination therapies are com-
plex. In order to attain quantitative understanding, a
micro-scale spatially explicit reaction-diffusion/convection
pharmacodynamics (microPD) model [19] parameterized
with experimental measurements from MiaPaCa-2 tumors
was developed to (refer to Additional file 1: Methods for
model parameters) 1) explore TH-302 tissue penetration,
2) monitor TH-302 activation and diffusion of the released
effector ± pyruvate, and 3) monitor tissue hypoxia ± pyru-
vate. For these analyses, tissue was digitized (Figure 6a) to
spatially inform simulations (Figure 6b–d) to show diffu-
sive distributions of oxygen, pyruvate, inactive TH-302,
and active TH-302 at varying distances from vasculature
(Figure 6b–d). The digitization contained individual
cells, as well as interstitial parenchyma, that have the
ability to consume oxygen, import pyruvate, and die
when exposed to active TH-302. Baseline simulations
showed that the hypoxia border (<10 mmHg) is, on
average, 110 μm from the vasculature (Figure 6b). The
measured diffusion distance of oxygen in tissue is
between 100 and 200 μm [28]. With the addition ofpyruvate (Figure 6c), cells closest to vasculature con-
sumed more oxygen, reducing oxygen diffusion (hypoxia
border = 76 μm) leading to a 30% hypoxia increase
(Figure 2c). The leftward shift of the hypoxia border is
paramount as the distance by which inactive TH-302 must
diffuse prior to activation is shortened, increasing the
region exposed to the effector threefold. TH-302
treatment in the presence of pyruvate increased cell death
(black dots) by 88% when compared to TH-302 alone
(Figure 6d). An unexpected result of these simulations was
a mechanism for tissue re-oxygenation following combin-
ation treatment. A rightward shift (T = 30 post TH-302) of
the hypoxia border from 76 to 104 μm occurs as oxygen
consumption decreases as cell death increases. These
simulations quantitatively illustrate how exogenous
pyruvate may increase local hypoxia and thereby improve
TH-302 efficacy.
Discussion
Because hypoxic tumors are poorly prognostic and resist-
ant to chemo- and radiotherapies, there has been intense
interest in agents that will target hypoxic volumes. HAPs
are a new class of anti-cancer therapeutics, and TH-302 is
a leading candidate in clinical trials. The pharmacody-
namic effects of these agents are complex and depend on
vascular delivery, tissue penetration-to-hypoxic volumes,
activation, and bystander killing. This is made even more
complex by the short plasma half-lives of these agents.
We thus contend that increased efficacy can be achieved
through transient exacerbation of hypoxia in combination
with advanced pharmacodynamics modeling. We have
shown that exogenous pyruvate transiently exacerbates
tumor hypoxia by increasing the rate of cellular OCR lead-
ing to improved TH-302 anti-tumor efficacy. This work
was performed in three PDAC models: Hs766t, MiaPaCa-
2, and SU.86.86 cells that have high, moderate, and low
sensitivity to TH-302 monotherapy, respectively. Molecu-
lar and metabolic characterizations of these cells and
tumors were consistent with their responses, as were their
responses to pyruvate in vitro and in vivo. As predicted,
pyruvate pretreatment caused a significant therapeutic
benefit to the intermediately sensitive MiaPaCa-2 tumors
exclusively. However, there were dramatic increases in
survival for Hs766t tumors, which are highly sensitive
to TH-302 monotherapy. Nonetheless, in contrast to
the strong in vitro and in vivo effects of pyruvate on
OCR and oxygen levels, the therapeutic benefits of
combining pyruvate with HAP therapy, albeit significant,
were only modest. Hence, we propose that additional
optimization of timing and dose, using in silico models,
can lead iteratively to improved therapeutic outcome of
this novel combination therapy.
While the effect of exogenous pyruvate on metabolism
has only recently been explored in the context of cancer
Figure 6 Oxygen and active TH-302 distribution in simulated MiaPaCa-2 tissue extracellular space. (a) A ROI of MiaPaCa-2 xenograft
tissue stained with CD-31 (i) was selected (ii) for segmentation (iii), and used as a domain for in-silico simulations of the interstitial transport of
oxygen (IV). (b,c) Temporal and spatial distributions of oxygen (1st column), pyruvate (2nd column), inactive TH-302 (3rd column) and active
TH-302 (4th column). The bar graphs show averaged amounts of the compound across the tissue slice. The vertical lines in oxygen bar graphs
show the border between the normoxic (left) and hypoxic (right) regions of the tissue. Black dots in the active TH-302 tissue graph represent
dead cells. (b) Initial distribution of oxygen before the treatment is applied. Pyruvate, inactive and active TH-302 are all absent. (c) Distributions of
chemical compounds 10 min after applying TH-302. In the bottom-row simulation pyruvate was applied 30 min before TH-302 (second column)
which resulted in decreased pO2 due to increased oxygen uptake by the cells exposed to pyruvate (first column), and in expanded region of
TH-302 activation (last column). (d) Distributions of chemical compounds 30 min after applying TH-302. In the bottom-row simulation, pyruvate
was applied 30 min before TH-302 (second column). The region of TH-302 activation in two-fold larger (yellow region in the last column), and
the number of death cells is 88% larger (black dots in the last column) when compared to simulation with TH-302 only.
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identified in neuronal models as the predominant mito-
chondrial substrate [10]. We therefore hypothesized that
reduced pO2 in pancreatic tumors by exogenous pyru-
vate was a result of elevated OCR. However, this does
not explain why exogenous pyruvate alone would stimu-
late oxygen consumption in cancer cells. MiaPaCa-2 and
Hs766t are glycolytic, implying that the pyruvate fluxshould be substantial and not limiting for mitochondrial
consumption. However, the OCRs of these two tumor
types were the most strongly affected by pyruvate. One
possible explanation is that PKM2, the enzyme that cata-
lyzes the dephosphorylation of phosphoenolpyruvate to
pyruvate, is located adjacent to the plasma membrane,
whereas the mitochondria are peri-nuclear [29,30]. The
rate of pyruvate production is regulated by PKM2 and
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transformed cells exhibiting glycolytic phenotypes. Since
enzymes of the lower half of glycolysis are localized near
the plasma membrane, we hypothesize that PKM2 is
closely associated spatially with these enzymes, making
the fate of pyruvate a readily available substrate for
lactate dehydrogenase, rather than transport into the
mitochondria [29]. Hence, PKM2-produced pyruvate must
traverse several microns of intracellular space, with diffu-
sion gradients and intervening bioconversions, before it
can be used to fuel respiration. With these distances,
reaction-diffusion models predict that the local concentra-
tion of pyruvate at PKM2 would have to be at least 100
times higher than the Km for mitochondrial consumption
for the mitochondrial pyruvate dehydrogenase to become
saturated [31].
In contrast, exogenous pyruvate may have a different
metabolic fate than pyruvate generated via glycolysis.
Following uptake, the process of converting pyruvate to
lactate continues as shown by hyperpolarized 13C pyruvate
MR studies. However, since exogenous pyruvate can bypass
PKM2, the available pyruvate concentration for transport
into the mitochondria increases, stimulating respiration.
Since pyruvate is delivered as a single bolus, exogenous
pyruvate is quickly metabolized and the effect on respir-
ation only transient; hence, the approximately 30-min
decrease of tumor pO2 in our pancreatic tumor model
(Figure 4).
Finally, chronic hypoxia has been shown to select for
cells that are resistant to apoptosis [32,33]. Hence, there
may be concern that exacerbating hypoxia may lead to
enhanced progression or therapy resistance. In contrast
to previous studies that induced hypoxia pharmacologic-
ally over many days [7], the current metabolic approach
lasts <1 h, which is consistent with the blood half-life of
TH-302. We contend that acute changes in pO2 will not
lead to enhanced proliferation or resistance, but this will
have to be investigated. Additionally, as pyruvate has
also been shown to increase OCR in neurons, glia, and
cardiac muscle [10-12], it is possible that this treatment
may lead to hypoxia in normal tissues and increase TH-
302 off-target effects. No increased toxicity of TH-302
was observed in our studies, and we reason that active
maintenance of vessel tone in normal tissues, in contrast
to tumors, exerts a protective effect by increasing blood
flow to volumes with higher respiration. Nonetheless,
further studies are warranted to investigate potential
synergism between compounds that exacerbate tumor
hypoxia and hypoxia-activated prodrugs.
Conclusions
PDAC has one of the worst prognoses of all cancers due to
limited efficacy of current therapies. The hypoxia-activated
prodrug, TH-302, has shown promise clinically butadvances are needed to improve its efficacy against late
stage pancreatic cancer. This study supports the concept
that temporarily increasing tumor hypoxia with pyruvate
can improve the efficacy of HAPs, including TH-302,
against PDAC and other cancer types in the clinic. While
the effect of pyruvate on TH-302 activity in vivo was
significant, future studies are necessary to optimize timing
and dose, using in silico models, iteratively leading to
improved therapeutic outcome of this novel combination
therapy.
Additional file
Additional file 1: Supplementary table and figures. This document
contains additional supplemental data and extended methods section for
the mathematical model. In total, one table and five supplemental figures
are included.
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